Although TET2 deletions and loss-of-function mutations are more frequent in myeloid malignancies, they were observed in approximately 2% of various B cell malignancies, including a total 5.7% of patients diagnosed with diffuse large B cell lymphoma (135). The gene discussed is TET2; the disease is myeloid neoplasm.